Sort
4,870 grants matching “glp 1”
Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults
$1,339,717Harshini Neelakantan · Ridgeline Therapeutics, Llc · R44 · FY2025 · AG
Universal room temperature stable influenza nanovaccine
$1,339,376Balaji Narasimhan · Iowa State University · R01 · FY2019 · AI
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors
$1,339,269D. Martin Watterson · Northwestern University At Chicago · U01 · FY2015 · AG
Antibody immunotherapeutics for biodefense against Lassa virus
$1,337,737Robert F Garry · Tulane University Of Louisiana · R01 · FY2013 · AI
Translational Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa
$1,336,892William A. Beltran · University Of Pennsylvania · R24 · FY2013 · EY
PET Imaging of Damaging Neuroinflammation in Alzheimer's Disease
$1,336,772Andrew Christian Larson · Einsenca Inc. · R44 · FY2024 · AG
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens
$1,334,916Terry L Bowlin · Microbiotix, Inc · U01 · FY2011 · AI
Oral Small Molecule STAT3 Inhibitor to Treat Cachexia in Chronic Kidney Disease
$1,330,109David John Tweardy · Tvardi Therapeutics, Inc. · R42 · FY2017 · DK
Molecular Mechanisms of Physiologic Beta Cell Growth in Juvenile Human Pancreas
$1,329,213Alvin Carter Powers · Vanderbilt University · UC4 · FY2014 · DK
Synthetic microparticle malaria vaccine
$1,328,587Thomas J Powell · Artificial Cell Technologies, Inc. · R44 · FY2015 · AI
SBIR Phase II: Novel Hyaluronan Enhanced Polymeric Trans-Catheter Aortic Valve
$1,325,562Todd Charles Tomba · Youngheartvalve Llc · R44 · FY2024 · HL
Theraupeutic Candidates for Huntington's Disease: From Lead to IND
$1,324,509Aleksey Gregory Kazantsev · Massachusetts General Hospital · U01 · FY2011 · NS
Lazzaro Medical Scaffold System for improved treatment of tracheobronchomalacia
$1,323,708Dawn Dawn Bitz · Lazzaro Medical, Inc. · R44 · FY2024 · HL
Nonalcoholic Steatohepatitis: Natural History, Pathogenesis and Therapy
$1,322,775Yaron Rotman · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
Therapeutic APOE2 overexpression for early Alzheimer's disease
$1,321,545Beverly L Davidson · Children'S Hosp Of Philadelphia · U01 · FY2021 · NS
Novel Antiangiogenic Peptides for Treatment of Exudative AMD
$1,320,393Nader Sheibani · University Of Wisconsin-Madison · R24 · FY2016 · EY
Regulators of Food Intake
$1,319,781Jonathan Krakoff · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
Glial Progenitor Cells for Treatment of ALS
$1,317,241Linda L Kelley · Johns Hopkins University · U01 · FY2012 · NS
Glial Progenitor Cells for Treatment of ALS
$1,317,241Nicholas J Maragakis · Johns Hopkins University · U01 · FY2012 · NS
Glial Progenitor Cells for Treatment of ALS
$1,309,432Nicholas J Maragakis · Johns Hopkins University · U01 · FY2014 · NS
Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer
$1,306,362Scott McNear Thacher · Orphagen Pharmaceuticals · R44 · FY2021 · CA
MolecularCellular Regulation of Hematopoiesis
$1,303,660Jonathan R Keller · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1
$1,301,808Karen E Hayes · Modulation Therapeutics, Inc. · R44 · FY2023 · CA
rAAV-CNGB3 Gene Therapy for Achromatopsia: Translational Research Studies
$1,298,215William W Hauswirth · University Of Florida · R24 · FY2015 · EY
A novel agent for preventing fatty degeneration of muscles in LGMD2B
$1,292,847Monique Floer · Advertent Biotherapeutics, Inc. · R44 · FY2025 · AR